Neil Kumar sold $4.2M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $52.20, traded Sep 4, 2025, filed Sep 8, 2025.
Score components
- +25RoleCEO
- +25Trade size$4.2M at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001742485-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -14,525 | $51.15 | $743k | 4,703,922 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,475 | $51.85 | $284k | 4,698,447 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -2,300 | $51.95 | $119k | 4,696,147 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -16,800 | $53.16 | $893k | 4,679,347 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -900 | $53.80 | $48k | 4,678,447 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -14,558 | $51.16 | $745k | 901,128 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,442 | $51.85 | $282k | 895,686 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -2,300 | $51.96 | $120k | 893,386 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -16,900 | $53.16 | $898k | 876,486 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -800 | $53.80 | $43k | 875,686 | Sep 8, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 43Moderate | BridgeBio Pharma, Inc. | Frank McCormick director | $3.9M 74,000 shares | -47% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.3M 26,156 shares | -10% | |
| 62Notable | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $2.1M 42,237 shares | -9% | |
| 40Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $872k 17,353 shares | -4% | |
| 40Moderate | BridgeBio Pharma, Inc. | Charles J Homcy director | $14M 300,000 shares | -25% | |
| 36Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $45k 1,000 shares | -1% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.7M 80,000 shares | -2% | |
| 28Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $841k 17,167 shares | -48% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.4M 80,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.